Natural Capsules Q4 & FY26 Results: Revenue Up 1.33 Cr, PAT at ₹4.98 Cr
Natural Capsules Limited reported Q4 FY26 revenue of ₹58.45 crore and PAT of ₹4.98 crore. For FY26, revenue was ₹187.20 crore with PAT at ₹(24.66) crore. The company expects revenue from a new HPMC line from H2 FY27. A collaboration with Fermbox Bio for fermentation technology was also announced.
The results show a recovery in profitability for the quarter due to specific operational factors. The introduction of a new product line and strategic API business development are positive but their full impact will be seen in future periods. The overall financial year still shows a net loss.
The company reported improved operational performance in Q4 FY26 due to deferred dispatches, leading to growth in topline and profitability. The readiness of a new HPMC line and progress in the API business, along with a strategic collaboration, indicate positive future prospects.
Natural Capsules Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported revenue of ₹58.45 crore for the quarter ended March 31, 2026, a significant increase from the previous period. Profit After Tax (PAT) for the quarter stood at ₹4.98 crore.
For the full financial year ended March 31, 2026, the company's revenue was ₹187.20 crore, with a PAT of ₹(24.66) crore. Mr. Sunil Mundra, Executive Director, commented that Q4 FY26 performance was strong operationally, driven by the dispatch of goods deferred due to the Puducherry plant shutdown, impacting standalone capsules business by approximately ₹6 crore. He also noted that the incremental HPMC line for double-zero capsules is ready and expected to generate revenue from the second half of the current financial year. The company anticipates FY27 to be a stable year for the capsules business, focusing on optimal capacity utilization and improved operational efficiency.
The API side saw commercial sales commence in Q4 FY26, with a focus on gradual volume growth. Additionally, a subsidiary, Natural Biogenex Private Limited, entered into definitive agreements with Fermbox Bio Private Limited for collaboration on advanced fermentation technology at the Tumkur facility. This arrangement aims to improve utilization of fermentation assets, create an additional revenue stream, and strengthen CDMO capabilities.
Mr. Mundra expressed confidence in scaling up the API business while driving higher profitability in the capsules business in the coming year, entering FY27 with improved operational visibility.
What to do with a filing like this
Natural Capsules Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natural Capsules Limited. Read the original for the full detail.